Michelle Monje-Deisseroth

Title: Michelle Monje-Deisseroth: Innovator in Cancer Treatment

Introduction

Michelle Monje-Deisseroth is a prominent inventor based in Stanford, CA (US). She has made significant contributions to the field of cancer treatment, particularly in the development of innovative immunotherapeutic methods. With a total of 4 patents, her work focuses on addressing critical challenges in oncology.

Latest Patents

Monje-Deisseroth's latest patents include groundbreaking inventions aimed at treating cancers harboring an H3K27M mutation. One of her notable patents is titled "Compositions and methods for treatment of cancers harboring an H3K27M mutation." This invention relates to immunotherapeutic treatment of cancer, specifically targeting diffuse midline glioma with the H3K27M mutation using immune cells engineered to express GD2-specific chimeric antigen receptors. Another significant patent is "Targeting pleiotrophin signaling to limit high-grade glioma invasion," which discloses methods of treating glioma by inhibiting pleiotrophin signaling to limit high-grade glioma invasion.

Career Highlights

Monje-Deisseroth is affiliated with Leland Stanford Junior University, where she continues her research and innovation in cancer therapies. Her work has garnered attention for its potential to improve treatment outcomes for patients with aggressive forms of cancer.

Collaborations

She collaborates with esteemed colleagues such as Robbie Majzner and Crystal L Mackall, contributing to a dynamic research environment focused on advancing cancer treatment methodologies.

Conclusion

Michelle Monje-Deisseroth stands out as a leading inventor in the field of cancer treatment, with her innovative patents paving the way for new therapeutic approaches. Her dedication to research and collaboration continues to inspire advancements in oncology.